Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

About Intercept Pharmaceuticals

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ICPT
  • CUSIP: 45845P10
Key Metrics:
  • Previous Close: $137.41
  • 50 Day Moving Average: $153.81
  • 200 Day Moving Average: $151.64
  • 52-Week Range: $89.76 - $217.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.79
  • P/E Growth: -1.35
  • Market Cap: $3.40B
  • Outstanding Shares: 24,726,000
  • Beta: -2.28
  • Net Margins: -5,003.95%
  • Return on Equity: -50.58%
  • Return on Assets: -45.49%
  • Current Ratio: 5.79%
  • Quick Ratio: 5.79%
Additional Links:
Companies Related to Intercept Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (?)
Ratings Breakdown: 4 Sell Ratings, 3 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.39)
Consensus Price Target: $187.11 (36.17% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateFirmActionRatingPrice TargetDetails
10/17/2016WedbushReiterated RatingOutperform$239.00View Rating Details
10/14/2016Leerink SwannReiterated RatingPositive$159.00View Rating Details
9/28/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
9/22/2016Robert W. BairdReiterated RatingOutperform$332.00View Rating Details
9/22/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
8/18/2016JMP SecuritiesReiterated RatingBuyView Rating Details
8/18/2016FBR & CoReiterated RatingMarket Perform$200.00View Rating Details
8/8/2016Cantor FitzgeraldReiterated RatingSell$60.00View Rating Details
8/5/2016Morgan StanleyReiterated RatingSell$80.00View Rating Details
8/5/2016BMO Capital MarketsReiterated RatingOutperform$219.00 -> $218.00View Rating Details
8/5/2016Oppenheimer Holdings Inc.Lower Price TargetOutperform$265.00 -> $250.00View Rating Details
8/5/2016LaidlawDowngradeBuy -> Sell$345.00 -> $105.00View Rating Details
6/1/2016Needham & Company LLCReiterated RatingBuy$350.00View Rating Details
6/1/2016Barclays PLCReiterated RatingBuy$200.00 -> $205.00View Rating Details
5/31/2016Cowen and CompanyBoost Price TargetOutperform$212.00 -> $215.00View Rating Details
5/31/2016Goldman Sachs Group Inc.Boost Price TargetNeutral$114.00 -> $128.00View Rating Details
4/9/2016Bank of America Corp.Reiterated RatingSell$144.00View Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91View Rating Details
8/7/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details
7/24/2015Royal Bank Of CanadaReiterated RatingOutperform$490.00View Rating Details
7/1/2015MLV & Co.Reiterated RatingHoldView Rating Details
3/27/2015Deutsche Bank AGBoost Price TargetBuy$300.00 -> $400.00View Rating Details
3/20/2015NomuraSet Price TargetBuy$440.00View Rating Details
12/18/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details
11/4/2014Summer StreetReiterated RatingPositiveView Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($5.17)$0.64 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.02)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($0.12)($0.79)$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014($0.72)($1.59)ViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
Current Year EPS Consensus Estimate: $-15.82 EPS
Next Year EPS Consensus Estimate: $-14.04 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($4.29)($3.65)($3.83)
Q2 20165($4.12)($3.00)($3.65)
Q3 20164($4.72)($2.80)($3.82)
Q4 20164($4.50)($2.68)($3.82)
Q1 20171($4.19)($4.19)($4.19)
Q2 20171($4.04)($4.04)($4.04)
Q3 20171($3.82)($3.82)($3.82)
Q4 20171($3.52)($3.52)($3.52)
(Data provided by Zacks Investment Research)


Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 81.83%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2016David ShapiroCMOSell411$153.34$63,022.74View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.40View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.04View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.00View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.60View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
News IconIntercept Pharmaceuticals Inc. (ICPT) Earns Outperform Rating from Wedbush - DailyQuint (NASDAQ:ICPT) - October 21 at 8:49 AM
News IconIntercept Pharmaceuticals Inc. (ICPT) Earns Positive Rating from ... - DailyQuint (NASDAQ:ICPT) - October 20 at 5:41 PM logoGilead Sciences Advances Fatty Liver Drug, Causing Some Head-Scratching (NASDAQ:ICPT) - October 20 at 5:41 PM logoVertex (VRTX) Q3 Earnings: What's in Store for the Stock? (NASDAQ:ICPT) - October 20 at 11:05 AM
News IconInsider Trading Roundup: Intercept Pharmaceuticals Inc (NASDAQ:ICPT) - The Voice Registrar (NASDAQ:ICPT) - October 18 at 10:41 AM logoIntercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC (NASDAQ:ICPT) - October 17 at 10:34 AM logoCompany Update (NASDAQ:ICPT): Intercept Pharmaceuticals Inc Receives Positive CHMP Opinion for Ocaliva for the ... - Smarter Analyst (NASDAQ:ICPT) - October 15 at 5:16 PM
News IconUpdate on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for the day (NASDAQ:ICPT) - October 15 at 10:19 AM logoIntercept Pharma Gets Positive CHMP Opinion For Ocaliva To Treat PBC (NASDAQ:ICPT) - October 14 at 5:28 PM logoIntercept’s Ocaliva Gets CHMP Nod in Europe (ICPT) (NASDAQ:ICPT) - October 14 at 5:28 PM logoIntercept Pharma (ICPT) Gains Positive CHMP Opinion for Ocaliva (NASDAQ:ICPT) - October 14 at 5:28 PM logoCompany Update (NASDAQ:ICPT): Intercept Pharmaceuticals Inc Receives Positive ... (NASDAQ:ICPT) - October 14 at 5:28 PM logoIntercept Liver Drug Gets Conditional EU OK (ICPT) (NASDAQ:ICPT) - October 14 at 5:28 PM logoIntercept Pharma (ICPT) Gains Positive CHMP Opinion for Ocaliva - (NASDAQ:ICPT) - October 14 at 8:43 AM logoIntercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the... (NASDAQ:ICPT) - October 14 at 8:42 AM logoIntercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union (NASDAQ:ICPT) - October 14 at 8:42 AM
News IconSell-side Consensus Sees Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Going Where Near-Term? - CSZ News (NASDAQ:ICPT) - October 13 at 5:36 PM logoINTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ICPT) - October 13 at 5:36 PM logoIntercept Pharmaceuticals Inc (ICPT) Reiterated at Outperform, as ... - TCC (NASDAQ:ICPT) - October 11 at 5:46 PM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Trading Up – Insiders Are Selling (NASDAQ:ICPT) - October 6 at 5:28 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - CSZ News (NASDAQ:ICPT) - October 5 at 5:30 PM
News IconInvestor News: Deadline upcoming in Settlement in the Lawsuit against Intercept Pharmaceuticals Inc (NASDAQ: ICPT) - GroundReport (NASDAQ:ICPT) - October 4 at 5:25 PM logoTARGET PharmaSolutions Announces the Launch of TARGET-PBC (Primary Biliary Cholangitis) (NASDAQ:ICPT) - October 4 at 10:20 AM
News IconInvestor News: Deadline upcoming in Settlement in the Lawsuit against Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (NASDAQ:ICPT) - October 4 at 10:20 AM logoNotable Monday Option Activity: ICPT, PG, SEAS (NASDAQ:ICPT) - October 3 at 5:17 PM logoIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : October 3, 2016 (NASDAQ:ICPT) - October 3 at 10:11 AM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Latest Broker ... - NewsDen (NASDAQ:ICPT) - October 2 at 4:57 PM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Latest Broker Views ... - NewsDen (NASDAQ:ICPT) - October 1 at 10:57 AM logoCan Shares Of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Hit $332? - Investor Newswire (NASDAQ:ICPT) - September 29 at 5:28 PM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Updated Broker Price Targets - The De Soto Edge (NASDAQ:ICPT) - September 29 at 5:28 PM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Trading Down – Insider Trading Activity (NASDAQ:ICPT) - September 29 at 10:37 AM logoDeadline Upcoming in $55 Million Settlement in the Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Investor Lawsuit (NASDAQ:ICPT) - September 28 at 10:26 AM
News IconAnalysts Predicting Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock Will Reach $60-332 Near Term - Frisco Fastball (NASDAQ:ICPT) - September 26 at 5:39 PM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Trading Up – Insiders Selling, Short Interest Growing (NASDAQ:ICPT) - September 24 at 5:08 PM logoIntercept Pharmaceuticals : to Present at Upcoming Investor Conferences (NASDAQ:ICPT) - September 24 at 5:08 PM
News IconSell-side Researchers are Predicting That Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares will Reach 188.1 ... - Frisco Fastball (NASDAQ:ICPT) - September 24 at 10:03 AM logoIntercept Pharmaceuticals Inc (ICPT) CEO & President Mark Pruzanski Sold $5.8 million of Shares - (NASDAQ:ICPT) - September 23 at 8:29 AM logoIntercept Pharmaceuticals Inc (ICPT) CEO & President Mark Pruzanski Sold $5.8 million of Shares (NASDAQ:ICPT) - September 23 at 8:29 AM
News IconBiotech Stocks To Put On Your Watch List: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Tokai Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ICPT) - September 21 at 3:47 PM
News IconAnalysts Valuations For Two Stocks: Iron Mountain Inc (NYSE:IRM), Intercept Pharmaceuticals Inc (NASDAQ:ICPT) - The Voice Registrar (NASDAQ:ICPT) - September 21 at 3:47 PM
News IconIntercept Pharmaceuticals Inc. (NASDAQ:ICPT) announced the filing of a New Drug Submission to Health Canada - Inside Trade (NASDAQ:ICPT) - September 21 at 3:47 PM logoIntercept Pharmaceuticals : Biotechnology Stocks Seeing Notable Strength In Afternoon Trading (NASDAQ:ICPT) - September 21 at 9:45 AM logoIntercept Pharma (ICPT) Files Obeticholic Acid NDS with Health Canada (NASDAQ:ICPT) - September 21 at 9:45 AM logoIntercept Pharmaceuticals Inc. (ICPT) Has Risen To Nearly A 1-Month High (NASDAQ:ICPT) - September 21 at 9:45 AM logoAllergan to buy Tobira in push for NASH treatments - Reuters (NASDAQ:ICPT) - September 20 at 10:40 AM logoIntercept Pharmaceuticals Inc. (ICPT) Has Risen To Nearly A 1-Month High - RTT News (NASDAQ:ICPT) - September 20 at 10:40 AM
News IconEarnings Estimates at a Glance for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Yankee Analysts (NASDAQ:ICPT) - September 19 at 5:37 PM logoIntercept Pharma (ICPT) Files Obeticholic Acid NDS with Health ... - (NASDAQ:ICPT) - September 19 at 5:37 PM logoIntercept Pharmaceuticals Files New Drug Submission to Health Canada for ... (NASDAQ:ICPT) - September 19 at 10:06 AM logo7:01 am Intercept Pharma announces the filing of a New Drug Submission to Health Canada, seeking Canadian marketing approval for obeticholic acid for the treatment of primary biliary cholangitis (NASDAQ:ICPT) - September 19 at 10:06 AM


Intercept Pharmaceuticals (NASDAQ:ICPT) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff